Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 1999

View Archived Issues

Immunomedics updates cancer therapeutics program following restructuring

Potential C. albicans vaccine tested in mice

Recombinant immunotoxin for hematological malignancies from NCI evaluated in phase I

Xoma and Genentech extend hu1124 agreement; present preliminary results from psoriasis trial

Structural Bioinformatics awarded SBIR grant for HER2 antagonists

New frontiers in gene therapy: treatment of erectile dysfunction

Further phase I data presented for bizelesin at AACR meeting

New compound for BPH in active preclinical development at Merck & Co. and Synaptic

BNP-7787 protects against taxane- and platinum-associated neurotoxicity

News from FASEB: novel botanical product for treatment of Alzheimer's disease

SBR-170: a new bioreductive alkylating agent selected for further evaluation

Avant Immunotherapeutics' CETP vaccine is effective in rabbit models of atherosclerosis

New, second-generation HIV fusion inhibitor from Trimeris to be evaluated clinically

First CpG DNA-based immunotherapeutic enters human trials

News from FASEB: YM-905 is a bladder-specific M3 receptor antagonist

Nonpeptide compounds derived from IL-1beta with peripheral analgesic activity

Novel antiepileptic drug from D-Pharm cleared for preliminary human trials

Preclinical study supports antinociceptive efficacy of ET-A antagonist

Preparation, activity, compositions and use of CCR3 receptor antagonists described by Roche

Akzo Nobel reports new agents for dysentery

Eisai research team discovers novel HIV-1 Tat antagonist

Bioglan and Allergan form psoriasis therapy partnership

FDA grants priority review status to Alza' sNDA for Doxil in ovarian cancer

New inhibitors of VCAM-1 binding to its receptor patented by Roche

Potent and long-lasting GnRH antagonist presented by Ferring

Potent and selective 5-HT1B/5-HT1D receptor agonists in the pipeline at Pierre Fabre

AACR news: squalamine evaluated for activity in prostate and lung cancer models

Health Canada grants priority review status for rofecoxib

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026